Abstract PO1-15-12: Circulating Tumor DNA (ctdna) for Prediction of Pathologic Complete Response (pcr) after 12 Weeks of Pembrolizumab + Trastuzumab + Pertuzumab in HER2-enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined